AVD

Business Context and Reporting Period

Company: American Vanguard Corporation (AVD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: A holding company operating primarily through its subsidiary, AMVAC Chemical Corporation, a specialty chemical manufacturer for agricultural and commercial uses. The company operates in a single reportable segment, focusing on insecticides, fungicides, herbicides, and soil fumigants. Key activities in 2005 included the acquisition of the Phorate insecticide product line and the Difenzoquat herbicide product line from BASF.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 26% to $189.8 million, driven by higher sales volume across most product lines and the inclusion of the newly acquired Phorate insecticide line from BASF.
• Margin Compression: Gross profit margins declined from 48% in 2004 to 45% in 2005 due to changes in the sales mix of products.
• Expense Increases: Operating expenses rose 13% to $53.4 million. Selling expenses increased due to payroll and advertising; General and Administrative expenses rose primarily due to legal fees (47% of the increase) related to ongoing litigation.
• Acquisitions: The company spent $22.1 million on intangible assets in 2005, primarily for the Phorate and Difenzoquat product lines.
• Debt Levels: Long-term debt increased significantly to fund acquisitions, with a new $20 million term loan and increased usage of the revolving credit line.

Guidance, Outlook, Risks, and Contingencies

Outlook and Capital Resources: Management anticipates continued investment in working capital and financing flexibility. In February 2006, the company completed a private placement of 1.04 million shares for net proceeds of approximately $22.5 million. The company maintains a $40 million availability under its revolving line of credit.

Significant Risks and Contingencies:

• DBCP Litigation: The company faces extensive litigation regarding 1,2-dibromo-3-chloropropane (DBCP) exposure.
  • Nicaragua: Approximately 66 suits filed under Public Law 364 involving ~2,261 plaintiffs, claiming $1 million in damages and $5 million in punitive damages each. The company contests jurisdiction but notes a risk of multi-million dollar judgments.
  • United States: Pending cases in California (Tellez and Mejia matters) involving Nicaraguan banana workers with trial dates scheduled for 2006. Cases in Hawaii, Mississippi, and Louisiana remain in procedural stages.
• Environmental Remediation: Ongoing investigation and potential remediation at the Commerce, California facility under the Expedited Remedial Action Program (ERAP). Costs are not currently expected to be material.
• Regulatory Compliance: Significant expenses are incurred for EPA data requirements and product registrations. Future testing requirements could delay sales or increase costs.
• Accounting Changes: Adoption of SFAS No. 123R in 2006 is expected to result in approximately $1.2 million in stock-based compensation expense over three years.

Key Facts for Investor Verification

• DBCP Exposure: Verify the status of the Nicaraguan Public Law 364 lawsuits and the potential for enforcement of judgments against the company, given the company's assertion that it lacks jurisdiction.
• Acquisition Integration: Assess the revenue contribution and profitability of the newly acquired Phorate and Difenzoquat product lines in subsequent quarters.
• Debt Covenants: Review the terms of the $80 million credit facility to ensure compliance with covenants, especially given the increased debt load.
• Customer Concentration: Note that three customers accounted for 39% of total sales in 2005 (15%, 13%, and 11%).
• Stock-Based Compensation: Monitor the impact of the new SFAS 123R standard on 2006 net income, estimated at $500,000 for the first year.